The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC).
Joel W. Neal
Research Funding - Roche/Genentech
Heather A. Wakelee
Research Funding - Roche/Genentech
Josephine Louella Feliciano
No relevant relationships to disclose
Sarah B. Goldberg
Consultant or Advisory Role - Boehringer Ingelheim
Research Funding - AstraZeneca
Daniel Morgensztern
No relevant relationships to disclose
Millie Snigdha Das
Honoraria - Genentech
Rebecca Suk Heist
Research Funding - Debiopharm Group; EMD Serono; Genentech; GlaxoSmithKline; Pfizer
Inga Tolin Lennes
No relevant relationships to disclose
Alona Muzikansky
No relevant relationships to disclose
Martin J. Edelman
No relevant relationships to disclose
Scott N. Gettinger
No relevant relationships to disclose
Lecia V. Sequist
Consultant or Advisory Role - AstraZeneca (U); Boehringer Ingelheim (U); Clovis (U); Merrimack Pharmaceuticals (U)
Research Funding - Genentech/OSI